

Unveiling Heterogeneity: The Pressing Challenge to Cancer Diagnosis and Therapy

Concettina La Motta*

Department of Pharmacy, University of Pisa, Pisa, Italy

Corresponding author: Concettina La Motta, Department of Pharmacy, University of Pisa, Pisa, Italy, Tel: +30 050 2219593; **E-mail:** concettina.lamotta@unipi.it

Since the pioneering studies of Heppner and co-workers on mouse mammary cancer [1], the presence of heterogeneous phenotypes and genotypes within the cancer bulk has been clearly demonstrated in several types of malignancies [2].

Different co-existing sub-populations, arising from both genetic and non-genetic variability and providing both heritable and non-heritable clones, give rise to an organized community in which not only cooperative but also conflicting interactions may set up. The resulting clonal crosstalk guarantees tumour growth, helping its spread through metastasis and the emergence of resistance to the commonly exploited anti-cancer treatments.

Although aware of tumour heterogeneity [2-6], we are still far from understanding how different phenotypes and genotypes interact, thus allowing the whole community to survive therapeutic selection and/or suppression. This is why we failed so far to fine-tune a long-lasting, effective treatment for this kind of pathology. Accordingly, untangle tumour complexity is a basic and urgent challenge scientists should not work around anymore.

Different kinds of cancer heterogeneity exist, regarding both inter-tumour and intra-tumour differences (Figure 1) [7]. Malignancies belonging to the same histopathological subtype but affecting different patients show genetic diversity, and are characterized by divergent functional behaviours. At the same time, malignancy affecting the same patient shows a marked variation too: the tumour bulk harbours both phenotypically and genotypically different cell populations (spatial heterogeneity), and heterogeneity may also arise when serial samples from the same patient are examined within the entire disease course (temporal heterogeneity).

A number of players take part to this heterogeneous tumour architecture. The main portion of the tumour bulk is made up of rapidly cycling and terminally differentiated cancer cells, but a small percentage of cells co-exist, bearing stem-like properties, whose origin is still a matter of debate [8-10]. They have been described as either arising from normal stem cells, as a result of epigenetic mutations, or deriving from more differentiated cells, which have acquired self-renewing ability through genetic modifications. As an alternative, Cancer Stem Cells (CSCs) may be generated by an Epithelial-to-Mesenchymal Transition (EMT), which allows the existing neoplastic cells to acquire mesenchymal traits and express stem-cell markers.

According to the hierarchical model of tumorigenesis, the so called 'cancer stem cell theory', CSCs play a key role in tumour perpetuating and progression, thanks to their indefinite self-renewal ability and aberrant differentiation capacity [11].

Received date: 03 Nov 2017; **Accepted date:** 07 Nov 2017; **Published date:** 05 Dec 2017.

Citation: La Motta C (2017) Unveiling Heterogeneity: The Pressing Challenge to Cancer Diagnosis and Therapy. *J Drug Res Dev* 4(1): doi <http://dx.doi.org/10.16966/2470-1009.e102>

Copyright: © 2017 La Motta C. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Moreover, differently from the bulk cells, CSCs resist to chemotherapy and radiotherapy. Indeed, cytotoxic treatments commonly exploited to target rapidly dividing cells are rather ineffective against this specific cancer sub-population, as it is characterized by a slow mitotic activity possibly associated with a quiescent G0/G1 state. Therefore, rather than being eradicated, CSCs turn out to be selected over the cancer bulk, being free to drive tumour relapse and mediate metastasis [12-16].

It is now clear that both CSCs and the non-stem differentiated tumor cells exist in a dynamic equilibrium, as the former can differentiate through asymmetric division and the latter can acquire CSC-like state. Any shift in this balance leads to a more CSC-rich tumor, which increases its aggressiveness worsening patients' prognosis.

The reversible and highly plastic stem-like state is modulated by micro environmental signals arising in the tumor niche [17-20]. Indeed, microenvironment surrounding the tumour bulk and comprising non-neoplastic cells like fibroblasts, adipocytes, infiltrating immune/inflammatory cells, as well as vessels and associated matrix, does not play a mere role of scaffold but rather participates actively in tumour growth modulation through both stimulatory and inhibitory signalling, thus further ravelling tumour complexity.

Bearing in mind the overall picture, a fruitful treatment of tumour should not ignore a careful selection of patients, made on the analysis of both tumour cells types and microenvironment hallmarks. In particular, the commonly available sequencing technologies should be used at




Figure 1: Inter-tumour and Intra-tumour Heterogeneity

diagnosis, to mark tumour heterogeneity, but also thereafter, to monitor cell differentiation during treatment response and point out the possible emergence of drug resistance during disease progression. Accounting for heterogeneity allows to choose the best personalized therapeutic approach which, in turn, should necessary combine agents targeting cancer's growth and survival, focusing in particular on CSCs, with derivatives targeting tumour microenvironment. Complementarity in the mechanism of actions of different compounds may merge, in principle, the best functional response with the lowest risk of drug resistance, thus helping to achieve a plain recovery.

References

1. Heppner GH (1984) Tumor heterogeneity. *Cancer Res* 44: 2259-2265.
2. Meacham CE, Morrison SJ (2013) Tumour heterogeneity and cancer cell plasticity. *Nature* 501: 328-337.
3. Marusyk A, Polyak K (2010) Tumor heterogeneity: causes and consequences. *Biochim Biophys Acta* 1805: 105-117.
4. Marusyk A, Almendro V, Polyak K (2012) Intra-tumour heterogeneity: a looking glass for cancer? *Nat Rev Cancer* 12: 323-334.
5. Tabassum DP, Polyak K (2015) Tumorigenesis: it takes a village. *Nat Rev Cancer* 15: 473-483.
6. De Sousa E Melo F, Vermeulen L, Fessler E, Medema JP (2013) Cancer heterogeneity--a multifaceted view. *EMBO Rep* 14: 686-695.
7. Bedard PL, Hansen AR, Ratain MJ, Siu LL (2013) Tumour heterogeneity in the clinic. *Nature* 501: 355-364.
8. Clarke MF, Dick JE, Dirks PB, Eaves CJ, Jamieson CH, et al. (2006) Cancer stem cells--perspectives on current status and future directions: AACR Workshop on cancer stem cells. *Cancer Res* 66: 9339-9344.
9. Rycaj K, Tang DG (2015) Cell-of-origin of cancer versus cancer stem cells: Assays and interpretations. *Cancer Res* 75: 4003-4011.
10. Greaves M, Maley CC (2012) Clonal evolution in cancer. *Nature* 481: 306-313.
11. Gil J, Stembalska A, Pesz KA, Sasiadek MM (2008) Cancer stem cells: the theory and perspectives in cancer therapy. *J Appl Genet* 49: 193-199.
12. Pattabiraman DR, Weinberg RA (2014) Tackling the cancer stem cells--what challenges do they pose? *Nat Rev Drug Discov* 13: 497-512.
13. Dagogo-Jack I, Shaw AT (2017) Tumour heterogeneity and resistance to cancer therapies. *Nat Rev Clin Oncol*.
14. Saunders NA, Simpson F, Thompson EW, Hill MM, Endo-Munoz L, et al. (2012) Role of intratumoural heterogeneity in cancer drug resistance: molecular and clinical perspectives. *EMBO Mol Med* 4: 675-684.
15. Maugeri-Saccà M, Vigneri P, De Maria R (2011) Cancer stem cells and chemosensitivity. *Clin Cancer Res* 17: 4942-4947.
16. Maugeri-Saccà M, Vici P, Di Lauro L, Barba M, Amoreo CA, et al. (2014) Cancer stem cells: are they responsible for treatment failure? *Future Oncol* 10: 2033-2044.
17. Plaks V, Kong N, Werb Z (2015) The cancer stem cell niche: How essential is the niche in regulating stemness of tumor cells? *Cell Stem Cell* 16: 225-238.
18. Lee G, Hall RR 3rd, Ahmed AU (2016) Cancer stem cells: cellular plasticity, niche, and its clinical relevance. *J Stem Cell Res Ther* 6: 363.
19. Kise K, Kinugasa-Katayama Y, Takakura N (2016) Tumour microenvironment for cancer stem cells. *Adv Drug Delivery Rev* 99: 197-205.
20. Ping YF, Zhang X, Bian XW (2016) Cancer stem cells and their vascular niche: Do they benefit from each other? *Cancer Lett* 380: 561-567.